Boosting 'good cholesterol' won't keep heart disease at bay after all - OregonLive.com

OregonLive.com

Boosting 'good cholesterol' won't keep heart disease at bay after all OregonLive.com That result is expected to lead doctors who prescribe niacin or other medications aimed at aggressively raising HDL, or high-density lipoproteins, to reconsider how they treat patients whose levels are low. Plus, pharmaceutical companies developing ... and more »

European expert presents new guidelines in cardio care - Philippine Star

European expert presents new guidelines in cardio care Philippine Star The guidelines also offer risk estimation charts and summaries of recommended goals on lipid-lowering therapy, and mention that LDL cholesterol remains as the primary treatment target. A section on medicine affecting HDL explains that “raising of HDL-C ...

Doctors Find Less Need For Abbott's 'Good Cholesterol' Pill - Forbes

Forbes

Doctors Find Less Need For Abbott's 'Good Cholesterol' Pill Forbes The brand name, known as Niaspan, was not long ago an increasingly used treatment in a physician's prescribing arsenal to protect against heart disease. So much was the case that Niaspan, the extended release formulation of generic niacin, ... and more »

Study questions whether raising “good" cholesterol reduces heart attack risk - Boston.com

Bloomberg

Study questions whether raising “good" cholesterol reduces heart attack risk Boston.com The results come shortly after a clinical trial of an HDL-raising drug being tested by the Swiss pharmaceutical giant Roche was halted, only the most recent high-profile problem to surface with a potential treatment aimed at lowering heart disease risk ... Genetic study questions HDL levels and the risk of MITheHeart.Org Raising HDL Levels May Not Lower Heart Attack RiskWebMD all 146 news articles »

Advanced Atherosclerosis: The Heart and Beyond - Medscape

Advanced Atherosclerosis: The Heart and Beyond Medscape In such populations, there tends to be high residual risk, even in aggressively treated patients. The premise of AIM-HIGH was to see if adding extended-release niacin to raise HDL cholesterol in patients who had already achieved a very low LDL ... and more »